OCULAR THERAPEUTIX, INC(OCUL)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

OCULAR THERAPEUTIX, INC (OCUL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OCUL at 8.4/100 on a 32-signal composite quality model, placing it at rank #2,930 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (2.8) and profitability (3.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), OCULAR THERAPEUTIX, INC reports quarterly revenue of $13.5M, net income of $-78.8M, free cash flow of $-70.6M. Top institutional holders of OCUL by reported 13-F value include FMR, Deep Track Capital, BlackRock, based on the most recent SEC filings. OCUL trades on the Nasdaq exchange and files with the SEC under CIK 1393434. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OCUL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OCULAR THERAPEUTIX, INC directly from SEC EDGAR.